|
1
|
Whelan J, McTiernan A, Cooper N, Wong YK,
Francis M, Vernon S and Strauss SJ: Incidence and survival of
malignant bone sarcomas in England 1979–2007. Int J Cancer.
131:E508–E517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grunewald TGP, Cidre-Aranaz F, Surdez D,
Tomazou EM, de Álava E, Kovar H, Sorensen PH, Delattre O and
Dirksen U: Ewing sarcoma. Nat Rev Dis Primers. 4:52018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stahl M, Ranft A, Paulussen M, Bölling T,
Vieth V, Bielack S, Görtitz I, Braun-Munzinger G, Hardes J, Jürgens
H and Dirksen U: Risk of recurrence and survival after relapse in
patients with Ewing sarcoma. Pediatr Blood Cancer. 57:549–553.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burchill SA: Ewing's sarcoma: Diagnostic,
prognostic, and therapeutic implications of molecular
abnormalities. J Clin Pathol. 56:96–102. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riggi N, Knoechel B, Gillespie SM,
Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE, Oksuz O,
Cook EB, et al: EWS-FLI1 utilizes divergent chromatin remodeling
mechanisms to directly activate or repress enhancer elements in
Ewing sarcoma. Cancer Cell. 26:668–681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sankar S, Bell R, Stephens B, Zhuo R,
Sharma S, Bearss DJ and Lessnick SL: Mechanism and relevance of
EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Oncogene. 32:5089–5100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chaturvedi A, Hoffman LM, Welm AL,
Lessnick SL and Beckerle MC: The EWS/FLI oncogene drives changes in
cellular morphology, adhesion, and migration in ewing sarcoma.
Genes Cancer. 3:102–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fadul J, Bell R, Hoffman LM, Beckerle MC,
Engel ME and Lessnick SL: EWS/FLI utilizes NKX2-2 to repress
mesenchymal features of Ewing sarcoma. Genes Cancer. 6:129–143.
2015.PubMed/NCBI
|
|
9
|
Pedersen EA, Menon R, Bailey KM, Thomas
DG, Van Noord RA, Tran J, Wang H, Qu PP, Hoering A, Fearon ER, et
al: Activation of Wnt/β-catenin in ewing sarcoma cells antagonizes
EWS/ETS function and promotes phenotypic transition to more
metastatic cell states. Cancer Res. 76:5040–5053. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Alava E, Kawai A, Healey JH, Fligman I,
Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR,
et al: EWS-FLI1 fusion transcript structure is an independent
determinant of prognosis in Ewing's sarcoma. J Clin Oncol.
16:1248–1255. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le Deley MC, Delattre O, Schaefer KL,
Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet
J, Ballet S, et al: Impact of EWS-ETS fusion type on disease
progression in Ewing's sarcoma/peripheral primitive neuroectodermal
tumor: Prospective results from the cooperative Euro-E.W.I.N.G. 99
trial. J Clin Oncol. 28:1982–1988. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Doorninck JA, Ji L, Schaub B, Shimada
H, Wing MR, Krailo MD, Lessnick SL, Marina N, Triche TJ, Sposto R,
et al: Current treatment protocols have eliminated the prognostic
advantage of type 1 fusions in Ewing sarcoma: A report from the
Children's Oncology Group. J Clin Oncol. 28:1989–1994. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Langfelder P and Horvath S: WGCNA: An R
package for weighted correlation network analysis. BMC
Bioinformatics. 9:5592008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saris CG, Horvath S, van Vught PW, van Es
MA, Blauw HM, Fuller TF, Langfelder P, DeYoung J, Wokke JH, Veldink
JH, et al: Weighted gene co-expression network analysis of the
peripheral blood from Amyotrophic Lateral Sclerosis patients. BMC
Genomics. 10:4052009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Savola S, Klami A, Myllykangas S, Manara
C, Scotlandi K, Picci P, Knuutila S and Vakkila J: High expression
of complement component 5 (C5) at tumor site associates with
superior survival in Ewing's sarcoma family of tumour patients.
ISRN Oncol 2011. 1687122011.
|
|
16
|
M K: Post-genome informatics.
2000.PubMed/NCBI
|
|
17
|
Volchenboum SL, Andrade J, Huang L,
Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U,
Triche TJ and Lawlor ER: Gene expression profiling of ewing sarcoma
tumors reveals the prognostic importance of tumor-stromal
interactions: A report from the Children's oncology group. J Pathol
Clin Res. 1:83–94. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kovar H, Dworzak M, Strehl S, Schnell E,
Ambros IM, Ambros PF and Gadner H: Overexpression of the
pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral
primitive neuroectodermal tumor. Oncogene. 5:1067–1070.
1990.PubMed/NCBI
|
|
19
|
Amos CI, Wu X, Broderick P, Gorlov IP, Gu
J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, et al:
Genome-wide association scan of tag SNPs identifies a
susceptibility locus for lung cancer at 15q25.1. Nat Genet.
40:616–622. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu P, Vikis HG, Wang D, Lu Y, Wang Y,
Schwartz AG, Pinney SM, Yang P, de Andrade M, Petersen GM, et al:
Familial aggregation of common sequence variants on 15q24-25.1 in
lung cancer. J Natl Cancer Inst. 100:1326–1330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang T, Chen T, Thakur A, Liang Y, Gao L,
Zhang S, Tian Y, Jin T, Liu JJ and Chen M: Association of PSMA4
polymorphisms with lung cancer susceptibility and response to
cisplatin-based chemotherapy in a Chinese Han population. Clin
Transl Oncol. 17:564–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Groettrup M, Soza A, Eggers M, Kuehn L,
Dick TP, Schild H, Rammensee HG, Koszinowski UH and Kloetzel PM: A
role for the proteasome regulator PA28alpha in antigen
presentation. Nature. 381:166–168. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rut W and Drag M: Human 20S proteasome
activity towards fluorogenic peptides of various chain lengths.
Biol Chem. 397:921–926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yano M, Koumoto Y, Kanesaki Y, Wu X and
Kido H: 20S proteasome prevents aggregation of heat-denatured
proteins without PA700 regulatory subcomplex like a molecular
chaperone. Biomacromolecules. 5:1465–1469. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rodig SJ, Gusenleitner D, Jackson DG,
Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C,
Weber JS, et al: MHC proteins confer differential sensitivity to
CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci
Transl Med. 10(pii): eaar33422018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakayama M: Antigen presentation by
MHC-dressed cells. Front Immunol. 5:6722014.PubMed/NCBI
|
|
27
|
Fogel M, Gutwein P, Mechtersheimer S,
Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M and
Altevogt P: L1 expression as a predictor of progression and
survival in patients with uterine and ovarian carcinomas. Lancet.
362:869–875. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fogel M, Mechtersheimer S, Huszar M,
Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P
and Gutwein P: L1 adhesion molecule (CD 171) in development and
progression of human malignant melanoma. Cancer Lett. 189:237–247.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zeimet AG, Reimer D, Huszar M, Winterhoff
B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen
LC, Petru E, et al: L1CAM in early-stage type I endometrial cancer:
Results of a large multicenter evaluation. J Natl Cancer Inst.
105:1142–1150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Altevogt P, Doberstein K and Fogel M:
L1CAM in human cancer. Int J Cancer. 138:1565–1576. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geismann C, Morscheck M, Koch D, Bergmann
F, Ungefroren H, Arlt A, Tsao MS, Bachem MG, Altevogt P, Sipos B,
et al: Up-regulation of L1CAM in pancreatic duct cells is
transforming growth factor beta1- and slug-dependent: Role in
malignant transformation of pancreatic cancer. Cancer Res.
69:4517–4526. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schafer H, Struck B, Feldmann EM, Bergmann
F, Grage-Griebenow E, Geismann C, Ehlers S, Altevogt P and Sebens
S: TGF-β1-dependent L1CAM expression has an essential role in
macrophage-induced apoptosis resistance and cell migration of human
intestinal epithelial cells. Oncogene. 32:180–189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Finas D, Huszar M, Agic A, Dogan S, Kiefel
H, Riedle S, Gast D, Marcovich R, Noack F, Altevogt P, et al: L1
cell adhesion molecule (L1CAM) as a pathogenetic factor in
endometriosis. Hum Reprod. 23:1053–1062. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Datta PK and Moses HL: STRAP and Smad7
synergize in the inhibition of transforming growth factor beta
signaling. Mol Cell Biol. 20:3157–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Halder SK, Anumanthan G, Maddula R, Mann
J, Chytil A, Gonzalez AL, Washington MK, Moses HL, Beauchamp RD and
Datta PK: Oncogenic function of a novel WD-domain protein, STRAP,
in human carcinogenesis. Cancer Res. 66:6156–6166. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pruksakorn D, Klangjorhor J,
Lirdprapamongkol K, Teeyakasem P, Sungngam P, Chaiyawat P,
Phanphaisarn A, Settakorn J and Srisomsap C: Oncogenic roles of
serine-threonine kinase receptor-associated protein (STRAP) in
osteosarcoma. Cancer Chemother Pharmacol. 82:1039–1047. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen G, Deng C and Li YP: TGF-β and BMP
signaling in osteoblast differentiation and bone formation. Int J
Biol Sci. 8:272–288. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Franchi A, Arganini L, Baroni G, Calzolari
A, Capanna R, Campanacci D, Caldora P, Masi L, Brandi ML and Zampi
G: Expression of transforming growth factor beta isoforms in
osteosarcoma variants: Association of TGF beta 1 with high-grade
osteosarcomas. J Pathol. 185:284–289. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nissenbaum J, Devor M, Seltzer Z, Gebauer
M, Michaelis M, Tal M, Dorfman R, Abitbul-Yarkoni M, Lu Y,
Elahipanah T, et al: Susceptibility to chronic pain following nerve
injury is genetically affected by CACNG2. Genome Res. 20:1180–1190.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu YL, Fann CS, Liu CM, Chen WJ, Wu JY,
Hung SI, Chen CH, Jou YS, Liu SK, Hwang TJ, et al: RASD2, MYH9, and
CACNG2 genes at chromosome 22q12 associated with the subgroup of
schizophrenia with non-deficit in sustained attention and executive
function. Biol Psychiatry. 64:789–796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yoo Y, Jung J, Lee YN, Lee Y, Cho H, Na E,
Hong J, Kim E, Lee JS, Lee JS, et al: GABBR2 mutations determine
phenotype in rett syndrome and epileptic encephalopathy. Ann
Neurol. 82:466–478. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Philpott AL, Fitzgerald PB, Bailey NW,
Churchyard A, Georgiou-Karistianis N and Cummins TD: A GABBR2 gene
variant modifies pathophysiology in Huntington's disease. Neurosci
Lett. 620:8–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
